Anti-tumor necrosis factor-α agents in noninfectious uveitis

Developments in Ophthalmology

Volumn 51, Issue , 2012, Pages 63-78

  Gueudry, Julie ^a   Lehoang, Phuc ^b   Bodaghi, Bahram ^b  

^a HÔPITAL CHARLES NICOLLE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNITY; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; METABOLISM; UVEITIS;

AUTOIMMUNITY; HUMANS; IMMUNOLOGIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84860875677     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000336187     Document Type: Article

References (115)

1. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R, Cerami A: Identity of tumour necrosis factor and the macrophagesecreted factor cachectin. Nature 1985;316:552-554. (Pubitemid 16239366)
2. Heiligenhaus A, Thurau S, Hennig M, Grajewski RS, Wildner G: Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol 2010;248: 1531-1551.
3. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ: TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-4627. (Pubitemid 34441368)
4. de Vos AF, Klaren VN, Kijlstra A: Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:3873-3883. (Pubitemid 24334545)
5. de Vos AF, van Haren MA, Verhagen C, Hoekzema R, Kijlstra A: Kinetics of intraocular tumor necrosis factor and interleukin-in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:1100-1106. (Pubitemid 24079844)
6. Woon MD, Kaplan HJ, Bora NS: Kinetics of cytokine production in experimental autoimmune anterior uveitis (EAAU). Curr Eye Res 1998;17:955-961. (Pubitemid 28468365)
7. Okada AA, Sakai J, Usui M, Mizuguchi J: Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:111-120. (Pubitemid 28380075)
8. Rosenbaum JT, Howes Jr. EL, Rubin RM, Samples JR: Ocular inflammatory effects of intravitreallyinjected tumor necrosis factor. Am J Pathol 1988; 133:47-53.
9. De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A: Tumour necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin production. Exp Eye Res 1995;60: 199-207.
10. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estevez E: Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLAB27. Curr Med Res Opin 2004;20:155-157. (Pubitemid 38197315)
11. Sakaguchi M, Sugita S, Sagawa K, Itoh K, Mochizuki M: Cytokine production by T cells infiltrating in the eye of uveitis patients. Jpn J Ophthalmol 1998;42: 262-268. (Pubitemid 28431799)
12. Kasner L, Chan CC, Whitcup SM, Gery I: The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1993;34:2911-2917. (Pubitemid 23269145)
13. Rosenbaum JT, Boney RS: Failure to inhibit endotoxin-induced uveitis with antibodies that neutralize tumor necrosis factor. Reg Immunol 1993;5: 299-303. (Pubitemid 24095095)
14. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-426. (Pubitemid 34429950)
15. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, Vredeveld CM: Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-440. (Pubitemid 36427629)
16. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS: A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23. (Pubitemid 40216347)
17. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A: Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062-1047.
18. Galor A, Perez VL, Hammel JP, Lowder CY: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-2323. (Pubitemid 44838928)
19. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK: Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritisassociated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-1150. (Pubitemid 46774863)
20. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-550. (Pubitemid 46580481)
21. Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-2451. (Pubitemid 41117431)
22. Imrie FR, Dick AD: Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-486. (Pubitemid 351339402)
23. Sharma SM, Nestel AR, Lee RW, Dick AD: Clinical review: anti-TNFalpha therapies in uveitis: perspective on years of clinical experience. Ocul Immunol Inflamm 2009;17:403-414.
24. Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A: Adalimumab (Humira): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol 2011;31:165-173.
25. Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, Bresci C, Lorusso M, Lepore L, Cimaz R: Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011;63:612-618.
26. Cordero-Coma M, Salom D, Diaz-Llopis M, Lopez-Prats MJ, Calleja S: Golimumab for uveitis. Ophthalmology 2011;118:1892, e1893-e1894.
27. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis P, Yazici H: Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007;46: 736-741. (Pubitemid 47061701)
28. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H: Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32: 98-105. (Pubitemid 40092599)
29. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001;358:295-296. (Pubitemid 32738970)
30. Arida A, Fragiadaki K, Giavri E, Sfikakis PP: Anti-TNF agents for Behcet's Disease: analysis of published data on patients. Semin Arthritis Rheum 2011;41:61-70.
31. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H: EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008;67:1656-1662.
32. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H: Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 2009;68:1528-1534.
33. Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, Lehoang P, Piette JC, Bodaghi B: Long-term efficacy and safety of lowdose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008;146:837-844, e831.
34. Mushtaq B, Saeed T, Situnayake RD, Murray PI: Adalimumab for sight-threatening uveitis in Behcet's disease. Eye (Lond) 2007;21:824-825. (Pubitemid 46909189)
35. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-1368. (Pubitemid 38879203)
36. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP: A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4-week study. Rheumatology (Oxford) 2011;50:593-597.
37. Diaz-Llopis M, Garcia-Delpech S, Salom D, Udaondo P, Hernandez-Garfella M, Bosch-Morell F, Quijada A, Romero FJ: Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351-361. (Pubitemid 351733224)
38. Callejas-Rubio JL, Sanchez-Cano D, Serrano JL, Ortego-Centeno N: Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:613-614, author reply 614.
39. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM: Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 2007;66:565-566. (Pubitemid 46580490)
40. Bawazeer A, Raffa LH, Nizamuddin SH: Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm 2010;18:226-232.
41. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M: Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010;94: 284-288.
42. Lee RW, Dick AD: Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behcet's uveitis. Br J Ophthalmol 2010;94:269-270.
43. El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002;109:2342-2346. (Pubitemid 35417121)
44. El-Shabrawi Y, Hermann J: Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al. Arthritis Rheum 2002;46:2821-2822, author reply 2822-2824.
45. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, Dougados M: Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-1634. (Pubitemid 44799677)
46. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H: Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68: 696-701.
47. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-392. (Pubitemid 38160763)
48. Marvillet I, Terrada C, Quartier P, Quoc EB, Bodaghi B, Prieur AM: Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine 2009;76:383-388.
49. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001;44:1411-1415. (Pubitemid 32537541)
50. Schmeling H, Horneff G: Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005;44:1008-1011. (Pubitemid 41487173)
51. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED: Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006;45:982-989. (Pubitemid 44283053)
52. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-324. (Pubitemid 46586527)
53. Vazquez-Cobian LB, Flynn T, Lehman TJ: Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-575. (Pubitemid 44468085)
54. Gallagher M, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS: Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007;91:1341-1344. (Pubitemid 47492870)
55. Mansour AM: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:274-276. (Pubitemid 46586514)
56. Baughman RP, Lower EE: Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-74. (Pubitemid 32280539)
57. Bargagli E, Olivieri C, Rottoli P: Cytokine modulators in the treatment of sarcoidosis. Rheumatol Int 2011;31:1539-1544.
58. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller Jr. W, Sands BE: A doubleblinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23: 201-208. (Pubitemid 47596315)
59. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, Drent M: Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008;31:1189-1196.
60. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT: A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-912. (Pubitemid 41057986)
61. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM: Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533-536. (Pubitemid 40569703)
62. Lahmer T, Knopf A, Lanzl I, Heemann U, Thuermel K: Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatol Int 2011, Epub ahead of print.
63. Niccoli L, Nannini C, Cassara E, Gini G, Lenzetti I, Cantini F: Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2009;93:1553-1554.
64. Wang Y, Gaudio PA: Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm 2008;16:167-171.
65. Baughman RP, Bradley DA, Lower EE: Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005;43:7-11. (Pubitemid 40123990)
66. Khalifa YM, Bailony MR, Acharya NR: Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab. Ocul Immunol Inflamm 2010;18:218-222.
67. Diaz Llopis M, Amselem L, Romero FJ, Garcia-Delpech S, Hernandez ML: Adalimumab therapy for Vogt-Koyanagi-Harada syndrome (in Spanish). Arch Soc Esp Oftalmol 2007;82:131-132.
68. Ziahosseini K, Newman WD: Challenges of managing sympathetic ophthalmia in a young child and the role of infliximab. J Pediatr Ophthalmol Strabismus 2011;48:e34-e36.
69. Menghini M, Frimmel SA, Windisch R, Meier FM: Efficacy of infliximab therapy in two patients with sympathetic ophthalmia. Klin Monbl Augenheilkd 2011;228:362-363.
70. Gupta SR, Phan IT, Suhler EB: Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol 2011;129:250-252.
71. Petropoulos IK, Vaudaux JD, Guex-Crosier Y: Anti-TNF-alpha therapy in patients with chronic noninfectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 2008;225:457-461. (Pubitemid 352016484)
72. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Mendez-Fernandez R, Lopez-Abad C, Matilla M, Garcia-Sanchez J: Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond) 2005;19:841-845. (Pubitemid 41195135)
73. Cheema RA, Al-Askar E, Cheema HR: Infliximab therapy for idiopathic retinal vasculitis, aneurysm, and neuroretinitis syndrome. J Ocul Pharmacol Ther 2011;27:407-410.
74. Cordero-Coma M, Benito MF, Hernandez AM, Antolin SC, Ruiz JM: Serpiginous choroiditis. Ophthalmology 2008;115:1633, e1631-e1632.
75. Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD, Rebello P, Waldmann H, Hale G, Forrester JV, Dick AD: Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 2004;122:845-851. (Pubitemid 38736243)
76. Bodaghi B, Bui Quoc E, Wechsler B, Tran TH, Cassoux N, Le Thi Huong D, Chosidow O, Herson S, Piette JC, LeHoang P: Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 2005;64:962-964. (Pubitemid 40733930)
77. Adan A, Sanmarti R, Bures A, Casaroli-Marano RP: Successful treatment with infliximab in a patient with diffuse subretinal fibrosis syndrome. Am J Ophthalmol 2007;143:533-534.
78. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
79. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Symmons DP: Drugspecific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2009; 69:522-528.
80. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-1894.
81. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puechal X, Wendling D, Lemann M, Ravaud P, Mariette X: Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-623.
82. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F, Finney D, Dixey J, Deighton C: BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49:2217-2219.
83. Simsek I, Erdem H, Pay S, Sobaci G, Dinc A: Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007;66:1255-1258. (Pubitemid 47309747)
84. Cunningham ET, Zierhut M: TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm 2010;18:421-423.
85. Stubgen JP: Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008;37:281-292.
86. Solomon AJ, Spain RI, Kruer MC, Bourdette D: Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler 2011;17:1472-1487.
87. Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E: Adalimumab-associated multiple sclerosis. J Rheumatol 2007;34:239-240, discussion 240.
88. Williams EL, Gadola S, Edwards CJ: Anti-TNFinduced lupus. Rheumatology (Oxford) 2009;48: 716-720.
89. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, Ruiz Del Agua A, Martinez A, Aarden L, Martin-Mola E, Balsa A: Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1445-1452.
90. Hashkes PJ, Shajrawi I: Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003;21:645-646. (Pubitemid 37236461)
91. Sturfelt G, Christensson B, Bynke G, Saxne T: Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 2007;34:2313-2314. (Pubitemid 350076897)
92. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J: Sarcoidlike granulomatosis in patients treated with tumor necrosis factor blockers: cases. Rheumatology (Oxford) 2009;48:883-886.
93. Louie GH, Chitkara P, Ward MM: Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis 2008;67:896-898. (Pubitemid 351829400)
94. Ko JM, Gottlieb AB, Kerbleski JF: Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of cases. J Dermatolog Treat 2009;20:100-108.
95. Lim LL, Fraunfelder FW, Rosenbaum JT: Do tumor necrosis factor inhibitors cause uveitis? A registrybased study. Arthritis Rheum 2007;56:3248-3252. (Pubitemid 47585419)
96. Cobo-Ibanez T, del Carmen Ordonez M, Munoz-Fernandez S, Madero-Prado R, Martin-Mola E: Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008;47:731-732. (Pubitemid 351619221)
97. Scrivo R, Spadaro A, Spinelli FR, Valesini G: Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008;58:1555-1556, author reply 1556-1557. (Pubitemid 351705951)
98. Kakkassery V, Mergler S, Pleyer U: Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35:751-756.
99. Reddy AR, Backhouse OC: Does etanercept induce uveitis? Br J Ophthalmol 2003;87:925.
100. Taban M, Dupps WJ, Mandell B, Perez VL: Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006;14:145-150. (Pubitemid 43890770)
101. Tiliakos AN, Tiliakos NA: Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary? J Rheumatol 2003;30:2727. (Pubitemid 37549362)
102. Kaipiainen-Seppanen O, Leino M: Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2003;62:88-89. (Pubitemid 36005808)
103. Handa T, Tsunekawa H, Zako M: Cataract surgery in Behcet's disease patients one week after infliximab administration. Case Report Ophthalmol 2011;2:176-178.
104. Sakai T, Kanetaka A, Noro T, Tsuneoka H: Intraocular surgery in patients receiving infliximab therapy for Behcet disease. Jpn J Ophthalmol 2010; 54:360-361.
105. Noda E, Yamanishi S, Shiraishi A, Ohashi Y: Cataract surgery under infliximab therapy in a patient with Behcet's disease. J Ocul Pharmacol Ther 2009;25:467-470.
106. Leccese P, Latanza L, D'Angelo S, Padula A, Olivieri I: Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet's disease to infliximab. Clin Exp Rheumatol 2011;29(suppl 67):S93.
107. Dhingra N, Morgan J, Dick AD: Switching biologic agents for uveitis. Eye (Lond) 2009;23:1868-1870.
108. Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y: Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 2011;31:243-245.
109. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P: Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010;117:1612-1616.
110. Manzano RP, Peyman GA, Carvounis PE, Damico FM, Aguiar RG, Ioshimoto GL, Ventura DF, Cursino ST, Takahashi W: Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit. J Ocul Pharmacol Ther 2011;27:327-331.
111. Manzano RP, Peyman GA, Carvounis PE, Kivilcim M, Khan P, Chevez-Barrios P, Takahashi W: Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 2008;246:907-911.
112. Tsilimbaris M, Diakonis VF, Naoumidi I, Charisis S, Kritikos I, Chatzithanasis G, Papadaki T, Plainis S: Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol 2009;247:1119-1125.
113. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N: Adverse events after intravitreal infliximab (Remicade). Retina 2010;30:71-80.
114. Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, Vergados IA: Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol 2009;247:273-281.
115. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP: Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009;147:825-830, e821.